Journal
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
Volume 10, Issue 8, Pages 671-682Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jash.2016.05.013
Keywords
Anti-androgen; diabetes mellitus; hypertension; placebo-controlled trial
Categories
Ask authors/readers for more resources
Diabetes predicts cardiovascular disease (CVD); some drugs are effective for CVD prevention but increase the risk of diabetes. In a systematic review and meta-analysis of placebo-controlled trials, we assessed if spironolactone, a mineralocorticoid receptor antagonist, affected glycemic control. We searched PubMed using (spironolactone or aldactone) and trial and (glucose or diabetes or insulin or insulin resistance) until January 4, 2016. In total, 18 eligible trials were identified; 10 on fasting glucose, 8 on hemoglobin A1c (HbA(1c)), 7 on homeostatic model assessment (HOMA)-insulin resistance (IR), and 8 on insulin. Spironolactone increased HbA(1c) (0.16%, 95% confidence interval 0.02 to 0.30) but had no clear effect on fasting glucose, HOMA-IR, and insulin. A mechanistic randomized controlled trial in people with and without diabetes might provide insight concerning these pleiotropic effects on diabetes and CVD relevant to prevention of both diseases. (C) 2016 American Society of Hypertension. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available